DOCETAXEL INJECTION 20 MG — DIN 02437031
DOCETAXEL : 20 MG · ACCORD HEALTHCARE INC · SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is DOCETAXEL INJECTION?
DOCETAXEL INJECTION 20 MG contains DOCETAXEL : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02437031, held by ACCORD HEALTHCARE INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 29-Oct-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is DOCETAXEL INJECTION used for?
Docetaxel Injection is indicated for the adjuvant treatment of patients with operable node-positive breast cancer in combination with doxorubicin and cyclophosphamide. It is also indicated for the treatment of patients with locally advanced or metastatic breast cancer, in combination with doxorubicin as first-line therapy, or in combination with capecitabine after failure of prior anthracycline-containing chemotherapy. Additionally, it is used for locally advanced or metastatic non-small cell lung cancer (monotherapy or with platinum derivatives), metastatic ovarian carcinoma after failure of chemotherapy, androgen-independent metastatic prostate cancer (with prednisone or prednisolone), and recurrent/metastatic squamous cell carcinoma of the head and neck (monotherapy after failure of previous chemotherapy).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Docetaxel cost around the world?
Docetaxel is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 20 | 37 | SAR███.██ |
| South Africa | single exit price | 29 | 29 | ZAR███.██ |
| Greece | producer price (ex-factory) | 18 | 18 | EUR███.██ |
| Italy | ex-factory (classe H) | 12 | 15 | EUR███.██ |
| Morocco | PPV (public price) | 9 | 13 | MAD███.██ |
| Romania | max producer price | 8 | 12 | RON███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 4 | 11 | BRL███.██ |
| Slovakia | categorised final price | 5 | 6 | EUR███.██ |
| Hungary | producer price (ex-factory) | 5 | 5 | HUF███.██ |
| Iceland | max wholesale | 5 | 5 | ISK███.██ |
| United Arab Emirates | public | 3 | 3 | AED███.██ |
| Bahrain | retail (max) | 2 | 3 | BHD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
162 pack listings across 124 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Docetaxel pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Docetaxel in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
9 holders have a Canadian DIN containing Docetaxel, across 15 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BIOLYSE PHARMA CORPORATION | 1 | 1 | DOCETAXEL INJECTION | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | DOCETAXEL INJECTION USP | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | DOCETAXEL INJECTION | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 3 | 0 | TARO-DOCETAXEL | No marketed DIN |
| ACTAVIS PHARMA COMPANY | 2 | 0 | ACT DOCETAXEL 40 MG/ML | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-DOCETAXEL | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 2 | 0 | TAXOTERE | No marketed DIN |
| TEVA CANADA LIMITED | 2 | 0 | DOCETAXEL INJECTION | No marketed DIN |
| ACCORD HEALTHCARE INC | 1 | 0 | DOCETAXEL INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | single-dose vials containing 20 mg (1 mL), 80 mg (4 mL) or 160 mg (8 mL) of docetaxel. Supplied as 5 ml vial and 6 ml vial (for 1 ml fill volume), 5 ml vial and 6 ml vial (for 4 ml fill volume) and 10 ml vial (for 8 ml fill volume). |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Docetaxel |
|---|---|
| ATC code | L01CD02 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02437031 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2437031 |
| Brand name | DOCETAXEL INJECTION |
| Generic / active ingredient | DOCETAXEL : 20 MG |
| Market authorization holder | ACCORD HEALTHCARE INC |
| Health Canada schedule | Prescription |
| ATC code | L01CD02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01CD |
| Current status | DORMANT |
| Status date | 29-Oct-2025 |
| Original market date | 2015-02-27 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Docetaxel in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 03 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 15 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOCETAXEL INJECTION | 10 MG | Injection | SANDOZ CANADA INCORPORATED | MARKETED | 02439336 |
| DOCETAXEL INJECTION | 20 MG | SOLUTION | BIOLYSE PHARMA CORPORATION | MARKETED | 02458020 |
| DOCETAXEL INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02361957 |
| ACT DOCETAXEL 40 MG/ML | 20 MG / 0.5 ML | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02444410 |
| ACT DOCETAXEL 40 MG/ML | 80 MG / 2 ML | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02441845 |
| DOCETAXEL INJECTION | 20 MG / 0.72 ML | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02412225 |
| DOCETAXEL INJECTION | 80 MG / 2.88 ML | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02412233 |
| PMS-DOCETAXEL | 20 MG / 0.5 ML | KIT ; SOLUTION | PHARMASCIENCE INC | CANCELLED PRE MARKET | 02436361 |
| PMS-DOCETAXEL | 80 MG / 2 ML | KIT ; SOLUTION | PHARMASCIENCE INC | CANCELLED PRE MARKET | 02436388 |
| TARO-DOCETAXEL | 160 MG / 8 ML | SOLUTION | TARO PHARMACEUTICALS INC | CANCELLED PRE MARKET | 02465655 |
2 · Same class — other molecules in ATC L01CD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Paclitaxel | ABRAXANE FOR INJECTABLE SUSPENSION · AJ-PACLITAXEL · APO-PACLITAXEL INJECTABLE · PACLITAXEL · +9 more | 19 | 5 | Yes |
| Cabazitaxel | CABAZITAXEL FOR INJECTION · JEVTANA | 7 | 5 | Yes |
| Docetaxel | ACT DOCETAXEL 40 MG/ML · DOCETAXEL INJECTION · DOCETAXEL INJECTION USP · PMS-DOCETAXEL · +2 more | 15 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01CE | Irinotecan · Topotecan | 32 | 12 |
| L01CA | Vinblastine · Vincristine · Vindesine · Vinorelbine | 22 | 7 |
| L01CB | Etoposide · Teniposide | 14 | 3 |
| L01CX | Trabectedin | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DOCETAXEL INJECTION called?
The same molecule, Docetaxel, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Docetaxel | Latin | Brazil, Iceland |
| Docetaxel Accord | Latin | Australia, Iceland |
| DOCETAXEL HOSPIRA | Latin | Saudi Arabia |
| Specrodoce | Latin | Saudi Arabia |
| TAXONTAS | Latin | Brazil |
| Docetaxel BOS | Latin | Saudi Arabia |
| Docetere | Latin | Saudi Arabia |
| LEXUS | Latin | Morocco |
| OKA-DOCETAXEL | Latin | Morocco |
| TAXOTERE | Latin | Bahrain |
| TEQUEL | Latin | Brazil |
| Docetaxel Hikma | Latin | Iceland |
| Docetaxel Kabi | Latin | Iceland |
| DOCETAXEL SPC | Latin | Bahrain |
| DOCETAXEL STADA | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.